This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Peter Riegman is a molecular biologist. Studied Biology 1982-1986 at Leiden University. PhD study on Prostate-Specific Antigen 1986-1992 at Erasmus University Rotterdam; Promotor: Prof. Dr. D. Bootsma, Co-promotor: Prof. Dr. J.
Trapman; 1992-1997 Postdoc meningioma and neurofibromatosis; Dr. E. Zwarthoff;: 1997-2001 Postdoc, neoplastic progression in Barrett's Esophagus; Dr. H van Dekken. From 2001 - present: Head of the Erasmus MC Tissue Bank, at
the Pathology Dept, Erasmus Medical Center, Rotterdam, where he became involved in European projects: TuBaFrost as coordinator, EurocanPlatform, BIOPOOL, SPIDIA, BBMRI, EuroBoNeT and SPIDIA4P and from the start of 2020 in Instand-NGS4P.
In 2010 he was ISBER president and ESBB president in 2011 and Section editor of Biopreservation and Biobanking. From 2012 - 2021 Erasmus MC Parelsnoer UMC and biobank coordinator. From 2012 NEN commissioner for CEN/TC140WG3
and ISO/TC212WG4. In 2018 he became advisor as well as board member in the Erasmus MC service platform of the Erasmus MC Central Biobank, when the Tissue bank became the Tissue collection point of the Central Biobank.
My name is Barbara Parodi, I work as Executive manager of the Biological Resource Centre of the Ospedale Policlinico San Martino in Genoa, Italy. I have been deeply involved in biobanking for many years, dealing with scientific,
organizational, technical and ethical issues. My expertise is mainly in management, quality assurance and quality control in biobanks, Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). I have participated
in the OECD Task Force on BRCs, as representative of the Italian Minister of Research (2000-2006), and I have contributed to the compilation of the OECD Best Practice Guidelines for Biological Resource Centres (2007). I belong
to the International Cell Line Authentication Committee. I have contributed to BBMRI since its Preparatory Phase. I take part in the Steering Committee of the Italian national node of BBMRI, with the role of project manager,
chair of the Biobank evaluation committee and responsible of the common service on quality. In ESBB I have served as treasurer and I serve now as ambassador.
Dr Balwir-Matharoo-Ball: Bal has a wealth of experience in academic research as well as the NHS. Bal is new Director of a Biobank in Abu Dhabi and previously was Deputy Director of the Biobank Nottingham University Hospitals
NHS Trust where she managed a team of 23 scientific and biomedical staff with a wide range of biobanking, informatics and technical skills. She is a member of European, Middle Eastern and African Society for Biopreservation
and Biobanking (ESBB) and serves as an Ambassador the promote the mission of ESBB. She served a term as councillor, President-elect, President, and past-President. Since 2016 Bal also serves as Co-Chair of the ESBB
Academic and Industry working group. The goal is to bring together a forum to enable and enhance public-private biobank related partnerships within the European framework and foster biobank-based R&D and innovation
within the pharmaceutical, biotech and ICT industry.Past positions held by Bal include Senior Post Doctoral Research Fellow for 12 years both at Nottingham Trent University and University of Nottingham. After gaining
her PhD in 1994 from Keele University Bal with her husband emigrated to Oman and took up a position as Head of Biomedical Sciences for the Ministry of Health.
Rosita Kammler heads the Translational Research Coordination at the ETOP IBCSG Partners Foundation, a clinical and translational cancer research foundation that recently merged out of the ETOP (European Thoracic Oncology
Platform) and IBCSG (International Breast Cancer Study Group). Her work has revolved around clinical trial biobanking, translational research coordination and project management for the past 20 years, and has gained
extensive experience in enabling global translational research that accesses biobanks. She has provided leadership for designing, building and conducting the translational research programs and biobanks for IBCSG and
ETOP, enabling state-of-the-art oncology translational research. She is responsible that the trial biosamples meet the objectives for quality, quantity, ethical use, to ensure the integrity of research data and analysis.
These biobanks have been a critical resource for the more than 40 translational research studies conducted by ETOP IBCSG, or collaborators. She is responsible for the management and oversight of all translational research
activities and biobanking activities conducted by IBCSG and ETOP in the course of prospective global clinical trials and retrospective biomarker analyses, including the ETOP Lungscape and Mesoscape iBiobanks. As newly
nominated ESBB Advisor, Rosita Kammler supports the Executive Board of the European, Middle East and Africa Society for Biopreservation and Biobanking. She served for a term as ESBB Councilor starting in 2016, ESBB
Vice-President 2018-2020, ESBB President 2020-2021, and ESBB Past President 2021-2022. She chairs the ESBB Sustainability Task Force, along with Lasse Boding, and serves as mentor of the ESBB GDPR and ELSI Working Group.
Erik Steinfelder earned his Bachelor of Science degree in Analytical Chemistry from the Saxion University of Applied Sciences in Deventer, Netherlands, and subsequently completed a degree in Foundations of Management at
Nyenrode Business University in Breukelen, Netherlands. In 2008, he joined Thermo Fisher Scientific, a multinational biotechnology product development company based in the US. In his position as first Biobank Commercial
Leader EMEA, he went on to head the complete biobank portfolio and range of activities and, most recently, became Corporate Accounts Executive. Additionally, between 2014 and 2017, he was also President-elect, President
and past President of ESBB, the European, Middle Eastern and African Society for Biopreservation and Biobanking. He started his position as Director General of BBMRI-ERIC on the 1st August 2017.
Pasquale De Blasio is the Founder and CEO of Integrated Systems Engineering (ISENET) leader in Tissue Microarray and Digital Pathology Platform with proven experience in Biobanking and iPS, spheroids and Organoids production,
Quality Control and Banking. Pasquale De Blasio was the Founding President of ESBB (European, Middle East and African Society for Biopreservation and Biobanking - www.esbb.org); and an active member of: (1) Marble Arch
International Experts Biobanking Group; (2) ISBER (International Society for Biological and Environmental Repositories - www.isber.org); (3) GET Consortium (Global Emerging Pathogens Treatment Consortium - http://www.getafrica.org/).
Pasquale De Blasio, is an expert in Biobanking Engineering and contributed to the establishment of The Qatar Biobanking for Medical Research – Population Biobank, NEUROMED Biobanking Center – Population Biobank, ISENET
Biobanking – Private Biobanking Service Provider, ISENET Biobanking – Private Service Provider, DIESSE Diagnosis of Siena – Pathogen Biobank (in progress). Pasquale De Blasio integrates multiple EU and National Research
Projects, published several scientific publications and registered 5 different patens.
